An Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H 2 Mab-19 Exerts Antitumor Activity in Mouse Colon Cancer Xenografts

Monoclon Antib Immunodiagn Immunother. 2020 Jun 18. doi: 10.1089/mab.2020.0009. Online ahead of print.

Abstract

Trastuzumab is a humanized antibody against human epidermal growth factor receptor 2 (HER2) that offers significant survival benefits to patients with HER2-overexpressing breast or gastric cancer. HER2 is also known to be overexpressed in colon cancers. In this study, a novel anti-HER2 monoclonal antibody (mAb), H2Mab-19 (IgG2b, κ) was characterized for its anticancer activity in colon cancers. H2Mab-19 showed both antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities against Caco-2, a colon cancer cell line. Furthermore, H2Mab-19 significantly reduced tumor development in a Caco-2 xenograft model. These results suggest that treatment with H2Mab-19 may be a useful therapy for patients with HER2-expressing colon cancers.

Keywords: HER2; antitumor activity; monoclonal antibody.